Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Roche’s RoActemra Recommended in Final U.K. Arthritis Guidance

Roche Holding AG’s RoActemra won the backing of the U.K.’s National Institute for Health and Clinical Excellence in final guidelines for treating patients with systemic juvenile idiopathic arthritis.

The guidelines would allow RoActemra as an option for children age 2 and older whose illness hasn’t adequately responded to other therapies, as long as Basel, Switzerland-based Roche makes the drug available to the state-run medical system at a discount, the institute, known as NICE, said today in an e-mailed statement.

NICE advises the National Health Service on the cost-effectiveness of treatments.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.